Lexaria Bioscience (LEXX) Operating Leases (2020 - 2026)

Lexaria Bioscience has disclosed Operating Leases across 6 years of filings, most recently posting $94386.0 for Q1 2026.

• Operating Leases for Q1 2026 came in at $94386.0, changed 0.0% year-over-year; the trailing twelve-month figure through Feb 2026 was $94386.0 (changed 0.0% YoY), and the FY2025 annual result was $78903.0, down 27.82% from the prior year.
• Operating Leases came in at $94386.0 for Q1 2026 at Lexaria Bioscience, up from $70819.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $116586.0 in Q2 2025 to a low of $18339.0 in Q2 2022.
• The 4-year median for Operating Leases is $94386.0 (2025), against an average of $79304.2.
• Across the five-year window, Operating Leases plunged 81.41% in 2022 and changed 0.0% in 2026, its largest moves.
• Lexaria Bioscience's Operating Leases stood at $18339.0 in 2022, then surged by 455.76% to $101920.0 in 2024, then tumbled by 30.52% to $70819.0 in 2025, then surged by 33.28% to $94386.0 in 2026.
• The last three Operating Leases figures came in at $94386.0 (Q1 2026), $70819.0 (Q4 2025), and $78903.0 (Q3 2025), per Business Quant data.